Introduction
Androgen deprivation therapy (ADT) for advanced prostate cancer is designed to disrupt the androgen receptor (AR) pathway (1) . The intended therapeutic target is the full-length androgen receptor (AR-FL), complete with an intact ligand-binding domain (LBD). Prostate tumors that progress despite first-line ADT (e.g., LHRH analogs), generally termed castration-resistant prostate cancer (CRPC), frequently demonstrate continued AR signaling driven by intratumoral androgens as well as elevated levels of AR-FL (2, 3) . In support of the importance of ligand-driven AR-FL signaling in CRPC, a number of clinically effective endocrine therapies targeting AR-LBD were recently developed to treat CRPC patients (e.g., abiraterone, MDV3100) (4, 5) . Nevertheless, the majority of patients progress shortly after treatment, again with reactivated AR signaling (4, 5) .
Androgen receptor splice variants that lack the functional LBD (AR-Vs) were recently decoded and characterized (6) (7) (8) (9) (10) (11) , with some (e.g., AR-V7, ARV567ES) (7, 9, 10) but not all (8) facilitating ligand-independent AR signaling in CRPC. AR-Vs originate from AR transcripts with insertions of cryptic exons downstream of the coding sequences for AR DNA-binding domain (DBD) (6, (9) (10) (11) , or with deletions of exons coding for AR-LBD (7, 8) . These alterations in AR transcripts disrupt the AR open reading frame, leading to truncated AR proteins with the intact N-terminal domain (NTD), AR-DBD, and a short variant-specific peptide replacing the functional AR-LBD. AR-Vs are capable of activating canonical AR-FL regulated genes (e.g., KLK3, TMPRSS2, NKX3.1) in the absence of AR-FL signaling (6) (7) (8) (9) (10) (11) , raising the possibility that AR-Vs and AR-FL may direct a similar transcriptional program, and that elevated AR-Vs in CRPC may compensate for AR-FL signaling. However, previous studies also suggest that AR-Vs are not as potent as AR-FL in inducing the expression of AR-FL genes (9) . Since AR-FL and AR-Vs are both overexpressed in CRPC, and AR-Vs are less abundant than AR-FL (6, 9) , the role of ligand-independent AR signaling in the context of suppressed yet still active AR- For siRNA treatment, cells reaching ~70% confluence were treated with siRNA for 24 hours and then cultured for 48 hours with or without 1 nM R1881. Target sequences for specific knockdown of different AR molecules were described previously (9) . MDV3100 was obtained from Medivation (San Francisco, CA). VCaP and LNCaP 95 cells were treated with MDV3100 dissolved in DMSO at the indicated concentrations for 24 hours with or without 1 nM R1881 (NEN). Transient transfection with AR-Vs was performed as described previously (7) (8) (9) .
Research. Western blot analysis. Antibodies utilized in this study include anti-AR N20 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-AR-V7, anti-PSA (Santa Cruz Biotechnology), anti-ERG (C-17, Santa Cruz Biotechnology), anti-UBE2C (Boston Biochem, Cambridge, MA), and anti-β-actin (SigmaAldrich, St. Louis, MO). The anti-AR-V7 antibody is a mouse monoclonal antibody developed using peptide sequences specific to AR-V7 (CKHLKMTRP) (Supplemental Figure 2) .
Immunofluorescence staining. Cells were grown on chamber slides to ~80% confluence in culture media supplemented with 10% FBS. At 24 hours after the indicated treatments, cells were fixed for 10 minutes using fresh made 4% paraformaldehyde and then with 0.2% Triton X-100 in 1x PBS for Gene set enrichment analysis. Expression data was generated using the Agilent Whole Genome Expression Arrays (Agilent Technologies, Santa Clara, CA) at Johns Hopkins University (by JL) and the University of Washington (by PSN), analyzed using GeneSpring GX 11.5 (Agilent Technologies), and subjected to gene set enrichment analysis (12) . Other details are described in Supplemental Methods. Raw expression microarray data have been submitted to GEO (GSE36549).
CRPC Xenografts. Abiraterone-treated xenograft tumor samples derived from the LuCaP35CR xenograft line was obtained from EAM. Detailed methods for treatment, tumor collection, and mRNA analysis were fully described previously (13) .
Tissue microarray analysis. CRPC tissues on the TMAs were procured as previously described (14) . Immunohistochemical staining for AR-V7, AR-FL, and UBE2C was optimized and performed by JE. De-paraffinized TMA slides were placed in 10 mM Tris, 1 mM EDTA (pH 9.0) and steamed for 40 min for antigen retrieval. The primary antibodies were incubated with each slide for 1 hour at room temperature. The EnVision reagent (DAKO Corp., Carpenteria, CA) was used for color development. Protein expression levels were scored by a semi-automated method as previously described (15) . Scoring data were analyzed using SPSS (SPSS Inc., Chicago, IL) and GraphPad (GraphPad Software, Inc., La Jolla, CA).
Results and Discussion
Regulation of AR-V expression by AR-FL. AR-FL and AR-V are both overexpressed in clinical CRPC specimens (9) , and induced in castrate conditions in CRPC xenografts (6) Figure 12) .
Correlation between AR-V and UBE2C after treatment with MDV3100 and abiraterone.
The "AR-V7 UP" gene set included UBE2C (Figure 2 Table I ). From these findings (Figures 1-3) , we reason that an adaptive shift toward AR-V mediated-signaling may contribute to resistance to MDV3100 and abiraterone. Table II) . AR-V7, but not AR-FL, is significantly correlated with UBE2C ( Figure 4B,   4C ), further supporting that AR-Vs, rather than AR-FL, mediates cell cycle gene expression in at least a subset of CRPC specimens. This protein expression data is consistent with findings from an mRNA based study demonstrating elevated cell cycle gene expression detected in bone metastasis expressing higher levels of AR-Vs (18).
In Vivo
In summary, this study reveals the functional interplay between AR-FL and AR-Vs when AR-LBD is rendered inactive by ADT. Importantly, the combined in vitro and in vivo data predict an adaptive shift toward AR-V-mediated signaling with effective CRPC therapies targeting AR-LBD.
These studies indicate that therapeutic efficacy of agents targeting AR-LBD may be compromised as a consequence of this adaptive shift, and that early detection of this shift may be utilized to guide treatment decisions. In addition, novel agents for CRPC (19) may be designed to suppress the activation of transcriptional programs directed by the AR-Vs. Overall, given the recently expanded therapeutic options for metastatic CRPC (20) , the present findings may stimulate efforts to target adaptive AR-V signaling for treatment selection and to overcome resistance to CRPC therapy. Research. 
